{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T18:53:56Z","timestamp":1778612036235,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40261-018-0739-9","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T22:20:48Z","timestamp":1546986048000},"page":"285-299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["HIV Integrase Inhibitor Pharmacogenetics: An Exploratory Study"],"prefix":"10.1007","volume":"39","author":[{"given":"Derek E.","family":"Murrell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Cluck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan P.","family":"Moorman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacy D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"Duffourc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-3756","authenticated-orcid":false,"given":"Sam","family":"Harirforoosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,8]]},"reference":[{"key":"739_CR1","unstructured":"HIV Data and Statistics. World Health Organization; 2017. \n                    https:\/\/www.who.int\/hiv\/data\/en\/\n                    \n                  .\u00a0Accessed 18 June 2017."},{"issue":"8","key":"739_CR2","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1086\/339751","volume":"34","author":"RG Hewitt","year":"2002","unstructured":"Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis. 2002;34(8):1137\u201342. \n                    https:\/\/doi.org\/10.1086\/339751\n                    \n                  .","journal-title":"Clin Infect Dis"},{"issue":"9","key":"739_CR3","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/infdis\/jis508","volume":"206","author":"M Gandhi","year":"2012","unstructured":"Gandhi M, Greenblatt RM, Bacchetti P, Jin C, Huang Y, Anastos K, et al. A single-nucleotide polymorphism in CYP2B6 leads to >\u20093-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J Infect Dis. 2012;206(9):1453\u201361. \n                    https:\/\/doi.org\/10.1093\/infdis\/jis508\n                    \n                  .","journal-title":"J Infect Dis"},{"key":"739_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/2394-2916.175388","volume":"3","author":"DE Murrell","year":"2016","unstructured":"Murrell DE, Harirforoosh S. Improving the renal profile of a human immunodeficiency virus drug combination through prodrug alteration. J Integr Nephrol Androl. 2016;3:2. \n                    https:\/\/doi.org\/10.4103\/2394-2916.175388\n                    \n                  .","journal-title":"J Integr Nephrol Androl"},{"issue":"6","key":"739_CR5","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1128\/AAC.06417-11","volume":"56","author":"ML Rizk","year":"2012","unstructured":"Rizk ML, Hang Y, Luo WL, Su J, Zhao J, Campbell H, et al. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother. 2012;56(6):3101\u20136. \n                    https:\/\/doi.org\/10.1128\/AAC.06417-11\n                    \n                  .","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"739_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2174\/1574886313666180116124046","volume":"13","author":"F Parant","year":"2018","unstructured":"Parant F, Miailhes P, Brunel F, Gagnieu MC. Dolutegravir-related neurological adverse events: a case report of successful management with therapeutic drug monitoring. Curr Drug Saf. 2018;13(1):69\u201371. \n                    https:\/\/doi.org\/10.2174\/1574886313666180116124046\n                    \n                  .","journal-title":"Curr Drug Saf"},{"issue":"1","key":"739_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/eri.11.157","volume":"10","author":"HW Lampiris","year":"2012","unstructured":"Lampiris HW. Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor. Expert Rev Anti-infect Ther. 2012;10(1):13\u201320. \n                    https:\/\/doi.org\/10.1586\/eri.11.157\n                    \n                  .","journal-title":"Expert Rev Anti-infect Ther"},{"issue":"5","key":"739_CR8","first-page":"904","volume":"19","author":"DE Murrell","year":"2015","unstructured":"Murrell DE, Moorman JP, Harirforoosh S. Stribild: a review of component characteristics and combination drug efficacy. Eur Rev Med Pharmacol Sci. 2015;19(5):904\u201314.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"739_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12981-016-0115-x","volume":"13","author":"J Jiang","year":"2016","unstructured":"Jiang J, Xu X, Guo W, Su J, Huang J, Liang B, et al. Dolutegravir(DTG, S\/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. AIDS Res Ther. 2016;13(1):30. \n                    https:\/\/doi.org\/10.1186\/s12981-016-0115-x\n                    \n                  .","journal-title":"AIDS Res Ther"},{"issue":"1","key":"739_CR10","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1186\/s12879-017-2717-x","volume":"17","author":"H Yagura","year":"2017","unstructured":"Yagura H, Watanabe D, Kushida H, Tomishima K, Togami H, Hirano A, et al. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis. 2017;17(1):622. \n                    https:\/\/doi.org\/10.1186\/s12879-017-2717-x\n                    \n                  .","journal-title":"BMC Infect Dis"},{"issue":"3","key":"739_CR11","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1097\/QAI.0000000000000057","volume":"65","author":"DA Wohl","year":"2014","unstructured":"Wohl DA, Cohen C, Gallant JE, Mills A, Sax PE, Dejesus E, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF versus single-tablet regimen efavirenz\/emtricitabine\/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65(3):e118\u201320. \n                    https:\/\/doi.org\/10.1097\/QAI.0000000000000057\n                    \n                  .","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9893","key":"739_CR12","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","volume":"382","author":"P Cahn","year":"2013","unstructured":"Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893):700\u20138. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(13)61221-0\n                    \n                  .","journal-title":"Lancet"},{"issue":"6","key":"739_CR13","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/tpj.2012.40","volume":"12","author":"JE Wyatt","year":"2012","unstructured":"Wyatt JE, Pettit WL, Harirforoosh S. Pharmacogenetics of nonsteroidal anti-inflammatory drugs. Pharmacogenomics J. 2012;12(6):462\u20137. \n                    https:\/\/doi.org\/10.1038\/tpj.2012.40\n                    \n                  .","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"739_CR14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/FTD.0b013e318296045b","volume":"35","author":"L Elens","year":"2013","unstructured":"Elens L, Capron A, van Schaik RH, De Meyer M, De Pauw L, Eddour DC, et al. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Ther Drug Monit. 2013;35(5):608\u201316. \n                    https:\/\/doi.org\/10.1097\/FTD.0b013e318296045b\n                    \n                  .","journal-title":"Ther Drug Monit"},{"issue":"4","key":"739_CR15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/tpj.2010.28","volume":"11","author":"D Wang","year":"2011","unstructured":"Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011;11(4):274\u201386. \n                    https:\/\/doi.org\/10.1038\/tpj.2010.28\n                    \n                  .","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"739_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2131\/jts.38.349","volume":"38","author":"M Okubo","year":"2013","unstructured":"Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, Yamazaki H. The CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J Toxicol Sci. 2013;38(3):349\u201354.","journal-title":"J Toxicol Sci"},{"issue":"3","key":"739_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1067\/mcp.2002.121371","volume":"71","author":"E Garcia-Martin","year":"2002","unstructured":"Garcia-Martin E, Martinez C, Pizarro RM, Garcia-Gamito FJ, Gullsten H, Raunio H, et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther. 2002;71(3):196\u2013204. \n                    https:\/\/doi.org\/10.1067\/mcp.2002.121371\n                    \n                  .","journal-title":"Clin Pharmacol Ther"},{"key":"739_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fgene.2013.00012","volume":"4","author":"K Klein","year":"2013","unstructured":"Klein K, Zanger UM. Pharmacogenomics of cytochrome P450 3A4: recent progress toward the \u201cmissing heritability\u201d problem. Front Genet. 2013;4:12. \n                    https:\/\/doi.org\/10.3389\/fgene.2013.00012\n                    \n                  .","journal-title":"Front Genet"},{"issue":"4","key":"739_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3390\/jpm2040175","volume":"2","author":"D Wang","year":"2012","unstructured":"Wang D, Sadee W. The making of a CYP3A biomarker panel for guiding drug therapy. J Pers Med. 2012;2(4):175\u201391. \n                    https:\/\/doi.org\/10.3390\/jpm2040175\n                    \n                  .","journal-title":"J Pers Med"},{"issue":"6","key":"739_CR20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1086\/507101","volume":"43","author":"MD Ritchie","year":"2006","unstructured":"Ritchie MD, Haas DW, Motsinger AA, Donahue JP, Erdem H, Raffanti S, et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis. 2006;43(6):779\u201382. \n                    https:\/\/doi.org\/10.1086\/507101\n                    \n                  .","journal-title":"Clin Infect Dis"},{"issue":"10","key":"739_CR21","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1093\/jac\/dkw215","volume":"71","author":"G Minuesa","year":"2016","unstructured":"Minuesa G, Arimany-Nardi C, Erkizia I, Cedeno S, Molto J, Clotet B, et al. P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+ P-gphigh cells and correlates with HIV-1 viral load. J Antimicrob Chemother. 2016;71(10):2782\u201392. \n                    https:\/\/doi.org\/10.1093\/jac\/dkw215\n                    \n                  .","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"739_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381. \n                    https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010\n                    \n                  .","journal-title":"J Biomed Inform"},{"key":"739_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku234","author":"A D\u2019Avolio","year":"2014","unstructured":"D\u2019Avolio A, Carcieri C, Cusato J, Simiele M, Calcagno A, Allegra S, et al. Intracellular accumulation of atazanavir\/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. J Antimicrob Chemother. 2014. \n                    https:\/\/doi.org\/10.1093\/jac\/dku234\n                    \n                  .","journal-title":"J Antimicrob Chemother"},{"key":"739_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.biopha.2014.11.007","volume":"69","author":"J Cusato","year":"2015","unstructured":"Cusato J, Allegra S, De Nicolo A, Boglione L, Fatiguso G, Cariti G, et al. ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. Biomed Pharmacother. 2015;69:63\u20139. \n                    https:\/\/doi.org\/10.1016\/j.biopha.2014.11.007\n                    \n                  .","journal-title":"Biomed Pharmacother"},{"key":"739_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jpba.2017.02.002","volume":"138","author":"M Simiele","year":"2017","unstructured":"Simiele M, Ariaudo A, De Nicolo A, Favata F, Ferrante M, Carcieri C, et al. UPLC\u2013MS\/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. J Pharm Biomed Anal. 2017;138:223\u201330. \n                    https:\/\/doi.org\/10.1016\/j.jpba.2017.02.002\n                    \n                  .","journal-title":"J Pharm Biomed Anal"},{"key":"739_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-1-61779-921-1_18","volume":"899","author":"D Cipriano","year":"2012","unstructured":"Cipriano D, Burnham M, Hughes JV. Effectiveness of various processing steps for viral clearance of therapeutic proteins: database analyses of commonly used steps. Methods Mol Biol. 2012;899:277\u201392. \n                    https:\/\/doi.org\/10.1007\/978-1-61779-921-1_18\n                    \n                  .","journal-title":"Methods Mol Biol"},{"issue":"2","key":"739_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","volume":"21","author":"JC Barrett","year":"2005","unstructured":"Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263\u20135. \n                    https:\/\/doi.org\/10.1093\/bioinformatics\/bth457\n                    \n                  .","journal-title":"Bioinformatics"},{"issue":"1","key":"739_CR28","doi-asserted-by":"publisher","first-page":"11008","DOI":"10.1038\/s41598-017-10812-1","volume":"7","author":"BP Prins","year":"2017","unstructured":"Prins BP, Kuchenbaecker KB, Bao Y, Smart M, Zabaneh D, Fatemifar G, et al. Genome-wide analysis of health-related biomarkers in the UK Household Longitudinal Study reveals novel associations. Sci Rep. 2017;7(1):11008. \n                    https:\/\/doi.org\/10.1038\/s41598-017-10812-1\n                    \n                  .","journal-title":"Sci Rep"},{"issue":"3","key":"739_CR29","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559\u201375. \n                    https:\/\/doi.org\/10.1086\/519795\n                    \n                  .","journal-title":"Am J Hum Genet"},{"key":"739_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000001781","author":"KJ Lepik","year":"2018","unstructured":"Lepik KJ, Yip B, Ulloa A, Wang L, Toy J, Akagi L, et al. Adverse drug reactions to integrase strand transfer inhibitors. Aids. 2018. \n                    https:\/\/doi.org\/10.1097\/qad.0000000000001781\n                    \n                  .","journal-title":"Aids"},{"issue":"5","key":"739_CR31","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/cpt.641","volume":"102","author":"S Hamzic","year":"2017","unstructured":"Hamzic S, Kummer D, Milesi S, Mueller D, Joerger M, Aebi S, et al. Novel genetic variants in carboxylesterase 1 predict severe early-onset capecitabine-related toxicity. Clin Pharmacol Ther. 2017;102(5):796\u2013804. \n                    https:\/\/doi.org\/10.1002\/cpt.641\n                    \n                  .","journal-title":"Clin Pharmacol Ther"},{"key":"739_CR32","unstructured":"Normal Ranges for Common Laboratory Tests; 2015. \n                    http:\/\/rml.rush.edu\/Pages\/RMLRangesCMP.aspx\n                    \n                  . Accessed 29 June 2018."},{"issue":"11","key":"739_CR33","doi-asserted-by":"publisher","first-page":"5472","DOI":"10.1128\/AAC.01235-13","volume":"57","author":"SL Ford","year":"2013","unstructured":"Ford SL, Gould E, Chen S, Margolis D, Spreen W, Crauwels H, et al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother. 2013;57(11):5472\u20137. \n                    https:\/\/doi.org\/10.1128\/AAC.01235-13\n                    \n                  .","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"739_CR34","doi-asserted-by":"publisher","first-page":"6244","DOI":"10.1128\/AAC.00795-16","volume":"60","author":"A Khatri","year":"2016","unstructured":"Khatri A, Trinh R, Zhao W, Podsadecki T, Menon R. Drug\u2013drug interaction between the direct-acting antiviral regimen of ombitasvir\u2013paritaprevir\u2013ritonavir plus dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine. Antimicrob Agents Chemother. 2016;60(10):6244\u201351. \n                    https:\/\/doi.org\/10.1128\/AAC.00795-16\n                    \n                  .","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"739_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/QAI.0b013e3181eb376b","volume":"55","author":"P German","year":"2010","unstructured":"German P, Warren D, West S, Hui J, Kearney BP. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr. 2010;55(3):323\u20139. \n                    https:\/\/doi.org\/10.1097\/QAI.0b013e3181eb376b\n                    \n                  .","journal-title":"J Acquir Immune Defic Syndr"},{"key":"739_CR36","unstructured":"Genvoya Prescribing Information. Gilead Sciences; 2017. \n                    http:\/\/www.gilead.com\/~\/media\/files\/pdfs\/medicines\/hiv\/genvoya\/genvoya_pi.pdf?la=en\n                    \n                  . Accessed 31 May 2017."},{"issue":"5","key":"739_CR37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/QAI.0b013e31802b4956","volume":"43","author":"M Markowitz","year":"2006","unstructured":"Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10\u00a0days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43(5):509\u201315. \n                    https:\/\/doi.org\/10.1097\/QAI.0b013e31802b4956\n                    \n                  .","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"739_CR38","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1345\/aph.1R468","volume":"46","author":"JL Olin","year":"2012","unstructured":"Olin JL, Spooner LM, Klibanov OM. Elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment. Ann Pharmacother. 2012;46(12):1671\u20137. \n                    https:\/\/doi.org\/10.1345\/aph.1R468\n                    \n                  .","journal-title":"Ann Pharmacother"},{"key":"739_CR39","doi-asserted-by":"publisher","DOI":"10.1097\/fpc.0000000000000308","author":"K Tsuchiya","year":"2017","unstructured":"Tsuchiya K, Hayashida T, Hamada A, Oki S, Oka S, Gatanaga H. High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants. Pharmacogenet Genom. 2017. \n                    https:\/\/doi.org\/10.1097\/fpc.0000000000000308\n                    \n                  .","journal-title":"Pharmacogenet Genom"},{"issue":"6","key":"739_CR40","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/clpt.2009.12","volume":"85","author":"LA Wenning","year":"2009","unstructured":"Wenning LA, Petry AS, Kost JT, Jin B, Breidinger SA, DeLepeleire I, et al. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin Pharmacol Ther. 2009;85(6):623\u20137. \n                    https:\/\/doi.org\/10.1038\/clpt.2009.12\n                    \n                  .","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"739_CR41","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1093\/jac\/dkw050","volume":"71","author":"C Barcelo","year":"2016","unstructured":"Barcelo C, Gaspar F, Aouri M, Panchaud A, Rotger M, Guidi M, et al. Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals. J Antimicrob Chemother. 2016;71(7):1933\u201342. \n                    https:\/\/doi.org\/10.1093\/jac\/dkw050\n                    \n                  .","journal-title":"J Antimicrob Chemother"},{"issue":"18","key":"739_CR42","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1097\/QAD.0000000000000863","volume":"29","author":"P Tebas","year":"2015","unstructured":"Tebas P, Kumar P, Hicks C, Granier C, Wynne B, Min S, et al. Greater change in bone turnover markers for efavirenz\/emtricitabine\/tenofovir disoproxil fumarate versus dolutegravir\u2009+\u2009abacavir\/lamivudine in antiretroviral therapy-naive adults over 144 weeks. Aids. 2015;29(18):2459\u201364. \n                    https:\/\/doi.org\/10.1097\/QAD.0000000000000863\n                    \n                  .","journal-title":"Aids"},{"issue":"3","key":"739_CR43","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/QAI.0b013e3182a97c39","volume":"64","author":"SK Gupta","year":"2013","unstructured":"Gupta SK, Mi D, Moe SM, Dube MP, Liu Z. Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial. J Acquir Immune Defic Syndr. 2013;64(3):279\u201383.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"739_CR44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.gene.2012.01.015","volume":"496","author":"M Hiyoshi","year":"2012","unstructured":"Hiyoshi M, Uemura H, Arisawa K, Nakamoto M, Hishida A, Okada R, et al. Association between the catechol-O-methyltransferase (rs4680: Val158Met) polymorphism and serum alanine aminotransferase activity. Gene. 2012;496(2):97\u2013102. \n                    https:\/\/doi.org\/10.1016\/j.gene.2012.01.015\n                    \n                  .","journal-title":"Gene"},{"issue":"11","key":"739_CR45","doi-asserted-by":"publisher","first-page":"6696","DOI":"10.1128\/AAC.03282-14","volume":"58","author":"I Song","year":"2014","unstructured":"Song I, Borland J, Chen S, Peppercorn A, Wajima T, Piscitelli SC. Effect of fosamprenavir\u2013ritonavir on the pharmacokinetics of dolutegravir in healthy subjects. Antimicrob Agents Chemother. 2014;58(11):6696\u2013700. \n                    https:\/\/doi.org\/10.1128\/AAC.03282-14\n                    \n                  .","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"739_CR46","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/157016211794582650","volume":"9","author":"H Teppler","year":"2011","unstructured":"Teppler H, Brown DD, Leavitt RY, Sklar P, Wan H, Xu X, et al. Long-term safety from the raltegravir clinical development program. Curr HIV Res. 2011;9(1):40\u201353. \n                    https:\/\/doi.org\/10.2174\/157016211794582650","journal-title":"Curr HIV Res"},{"issue":"5","key":"739_CR47","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/QAI.0000000000000222","volume":"66","author":"K Tsuchiya","year":"2014","unstructured":"Tsuchiya K, Hayashida T, Hamada A, Kato S, Oka S, Gatanaga H. Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants. J Acquir Immune Defic Syndr. 2014;66(5):484\u20136. \n                    https:\/\/doi.org\/10.1097\/QAI.0000000000000222\n                    \n                  .","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"739_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/QAI.0000000000000893","volume":"72","author":"K Tsuchiya","year":"2016","unstructured":"Tsuchiya K, Hayashida T, Hamada A, Oka S, Gatanaga H. Brief report: high peak level of plasma raltegravir concentration in patients with ABCB1 and ABCG2 genetic variants. J Acquir Immune Defic Syndr. 2016;72(1):11\u20134. \n                    https:\/\/doi.org\/10.1097\/QAI.0000000000000893\n                    \n                  .","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"739_CR49","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","volume":"2","author":"JM Molina","year":"2015","unstructured":"Molina JM, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96\u00a0week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2(4):e127\u201336. \n                    https:\/\/doi.org\/10.1016\/S2352-3018(15)00027-2\n                    \n                  .","journal-title":"Lancet HIV"},{"issue":"19","key":"739_CR50","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","volume":"369","author":"SL Walmsley","year":"2013","unstructured":"Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, et al. Dolutegravir plus abacavir\u2013lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807\u201318. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1215541\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"7","key":"739_CR51","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1473-3099(14)70782-0","volume":"14","author":"JR Arribas","year":"2014","unstructured":"Arribas JR, Pialoux G, Gathe J, Di Perri G, Reynes J, Tebas P, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48\u00a0week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis. 2014;14(7):581\u20139. \n                    https:\/\/doi.org\/10.1016\/S1473-3099(14)70782-0\n                    \n                  .","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"739_CR52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1310\/hct1502-51","volume":"15","author":"A Mills","year":"2014","unstructured":"Mills A, Crofoot G, Ortiz R, Rashbaum B, Towner W, Ward D, et al. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate\/emtricitabine to once-daily elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48\u00a0weeks data. HIV Clin Trials. 2014;15(2):51\u20136. \n                    https:\/\/doi.org\/10.1310\/hct1502-51\n                    \n                  .","journal-title":"HIV Clin Trials"},{"issue":"4","key":"739_CR53","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/QAI.0000000000001269","volume":"74","author":"A Fettiplace","year":"2017","unstructured":"Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V, et al. Psychiatric symptoms in patients receiving dolutegravir. J Acquir Immune Defic Syndr. 2017;74(4):423\u201331. \n                    https:\/\/doi.org\/10.1097\/QAI.0000000000001269\n                    \n                  .","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9692","key":"739_CR54","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","volume":"374","author":"JL Lennox","year":"2009","unstructured":"Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692):796\u2013806. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(09)60918-1\n                    \n                  .","journal-title":"Lancet"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0739-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-018-0739-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0739-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T19:09:12Z","timestamp":1578424152000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-018-0739-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,8]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["739"],"URL":"https:\/\/doi.org\/10.1007\/s40261-018-0739-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,8]]},"assertion":[{"value":"8 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was funded in part by a Research and Development Committee Interdisciplinary Grant and a Graduate Studies Student Research Grant from East Tennessee State University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All study procedures were conducted in accordance with the 1964 Helsinki Declaration (and its amendments). The study was approved by the East Tennessee State University\/Veterans Affairs Medical Campus Institutional Review Board (IRB#: 1214.4sw).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from study participants in the presence of at least one investigator and witness.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}